Rating Change
Citigroup analysts reiterated a Buy rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on August 03, 2026.
reiterateNASDAQ:AMLX
Citigroup Reiterates Buy Rating on Amylyx Pharmaceuticals, Inc. (AMLX)
Rating Change Citigroup analysts reiterated a Buy rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on August 03, 2026. Market Context Amylyx Pharmaceuticals, Inc.
Market Context
Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $20.17 with a market capitalization of $1.3B.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amylyx Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amylyx Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 03, 2026 | Citigroup | Buy | N/A |
| Jul 20, 2026 | Mizuho | Outperform | N/A |
| Jun 25, 2026 | Guggenheim | Buy | N/A |
| Apr 28, 2026 | Mizuho | Outperform | N/A |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AMLX Stock Page
Frequently Asked Questions
What does a Buy rating mean for AMLX?
A Buy rating from Citigroup reflects the analyst's outlook on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMLX forecast page.